Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Matthew Witkin"'
Autor:
Scott A. Armstrong, Andrew L. Kung, James E. Bradner, Andrei V. Krivtsov, Jun Qi, Matthew Witkin, Janna Minehart, Sridhar Vempati, Tina Davis, Megan Bariteau, Wonil Kim, Matthew C. Stubbs
Supplementary Table S1-S3 Legends and Supplementary Figure S1-S6 Legends. Legends for supplementary tables S1-S3 and supplementary figures S1-S6 which support data in the manuscript, but could not be included due to space constraints.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3278aefd41ce661123c8d89f8a1fbe
https://doi.org/10.1158/1078-0432.22457502
https://doi.org/10.1158/1078-0432.22457502
Autor:
Scott A. Armstrong, Andrew L. Kung, James E. Bradner, Andrei V. Krivtsov, Jun Qi, Matthew Witkin, Janna Minehart, Sridhar Vempati, Tina Davis, Megan Bariteau, Wonil Kim, Matthew C. Stubbs
Purpose: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23835c0d6e053bece84a8c34a9edfe1b
https://doi.org/10.1158/1078-0432.c.6523596
https://doi.org/10.1158/1078-0432.c.6523596
Autor:
Scott A. Armstrong, Andrew L. Kung, James E. Bradner, Andrei V. Krivtsov, Jun Qi, Matthew Witkin, Janna Minehart, Sridhar Vempati, Tina Davis, Megan Bariteau, Wonil Kim, Matthew C. Stubbs
Supplementary Tables S1-S3 and Supplementary Figures S1-S6. Table S1 - EC50 values for B-cell malignancies treated with HDAC inhibitors of varying isoform selectivity Table S2 - EC50 values for B-ALL cell line treated with a panel of HDAC inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7143001f9200b368a485c2b60c71fd9a
https://doi.org/10.1158/1078-0432.22457499
https://doi.org/10.1158/1078-0432.22457499
Autor:
Eneda Toska, Emiliano Cocco, Jane Park, Jorge S. Reis-Filho, Ross L. Levine, Pier Selenica, Jordan E. Otto, Maurizio Scaltriti, Fan Wu, Clayton K. Collings, Lorenzo Ferrando, Komal Jhaveri, Carmen Chan, Erik Ladewig, Huiyong Zhao, José Baselga, Yanyan Cai, Sagar Chhangawala, Mirna Sallaku, Cristian Serna-Tamayo, Pedram Razavi, Richard Koche, Andrew R. D’Avino, Christina S. Leslie, Guotai Xu, Alison Zhao, Arnaud Da Cruz Paula, Yuanming Cheng, Cigall Kadoch, Xuan Qu, Matthew Witkin
Publikováno v:
Nat Genet
Mutations in ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, are the most common alterations of the SWI/SNF complex in estrogen-receptor-positive (ER(+)) breast cancer. We identify that ARID1A inactivating mutations are present at a hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6831539292f54e66229366efec6b2e61
https://doi.org/10.1038/s41588-019-0554-0
https://doi.org/10.1038/s41588-019-0554-0
Autor:
Noushin Farnoud, Lihua Zou, Bradley E. Bernstein, Peter van Galen, Lauren Dong, Franck Rapaport, Keith B. Cordner, Jun Qi, Matthew Witkin, Richard Koche, Sofie De Groote, Erin McGovern, Juan Medina, Corinne E. Hill, James E. Bradner, Maria Kleppe, Ross L. Levine, Jaime M. Reyes, Efthymia Papalexi, Justin M. Roberts, Raajit K. Rampal, Matthew D. Keller, Julie Teruya-Feldstein, Amritha Varshini Hanasoge Somasundara
Publikováno v:
Cancer Cell. 33:785-787
Summary Genetic and functional studies underscore the central role of JAK/STAT signaling in myeloproliferative neoplasms (MPNs). However, the mechanisms that mediate transformation in MPNs are not fully delineated, and clinically utilized JAK inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a75b5e881ef6336d3a41fff5d278213a
https://doi.org/10.1016/j.ccell.2018.03.024
https://doi.org/10.1016/j.ccell.2018.03.024
Autor:
Travis J. Hollmann, Fei Chen, Jing Hu, Joan Massagué, Nicolas Lecomte, Christine A. Iacobuzio-Donahue, Yun-Han Huang, Harihar Basnet, Peter J. Allen, Steven D. Leach, Matthew Witkin, Charles J. David
Publikováno v:
Cancer Discov
TGFβ is an important tumor suppressor in pancreatic ductal adenocarcinoma (PDA), yet inactivation of TGFβ pathway components occurs in only half of PDA cases. TGFβ cooperates with oncogenic RAS signaling to trigger epithelial-to-mesenchymal transi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61ddfe9901fae89bd529a3102d337e86
https://pubmed.ncbi.nlm.nih.gov/31582374
https://pubmed.ncbi.nlm.nih.gov/31582374
Autor:
Timour Baslan, Richard Koche, S. E. Redlich, Benjamin H. Durham, Aaron D. Viny, Vincent-Philippe Lavallée, Elham Azizi, Robert L. Bowman, Anastasia Navitski, Dana Pe'er, Wenbin Xiao, Stephanie Braunstein, Matthew Witkin, Ross L. Levine, Jae H. Park, Yu Liu, Christopher J. Ott, Job Dekker
Transcriptional regulators, including the cohesin complex member STAG2, are recurrently mutated in cancer. The role of STAG2 in gene regulation, hematopoiesis, and tumor suppression remains unresolved. We show Stag2 deletion in hematopoietic stem/pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43ddbdf20ac95886598c27a1ac7ceb59
https://doi.org/10.1101/581868
https://doi.org/10.1101/581868
Autor:
Qing V. Li, Qiong Wang, Miguel Crespo, Dapeng Yang, Todd Evans, Gary Dixon, Richard Koche, Friederike Dündar, Paul Zumbo, Miriam Gordillo, Abhijit Shukla, Shuibing Chen, Renhe Luo, Chunlong Xu, Bess P. Rosen, Joan Massagué, Ralph Garippa, Matthew Witkin, Chew Li Soh, Danwei Huangfu, Nipun Verma, Qing Xiang, Michael A. Beer, Doron Betel
Publikováno v:
Nature genetics
Human embryonic stem cells (ESCs) and human induced pluripotent stem cells hold great promise for cell-based therapies and drug discovery. However, homogeneous differentiation remains a major challenge, highlighting the need for understanding develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::595ec43a4e36057eb7153240d37e1277
https://pubmed.ncbi.nlm.nih.gov/31110351
https://pubmed.ncbi.nlm.nih.gov/31110351
Autor:
Jane Park, Srinivasaraghavan Kannan, Eneda Toska, Maurizio Scaltriti, Charles L. Sawyers, Emiliano Cocco, Ralf Jauch, Wouter R. Karthaus, Dara S. Ross, Daisylyn Senna Tan, Yanyan Cai, Fan Wu, Erik Ladewig, Mirna Sallaku, Matthew Witkin, José Baselga, Jesper L.V. Maag, Jorge S. Reis-Filho, Sik Y. Ho, Chandra S. Verma, Srushti Kittane, Barbara Acevedo, Amaia Arruabarrena-Aristorena, Lorenzo Ferrando, Richard Koche, Pier Selenica, Pedram Razavi
Publikováno v:
Cancer Cell
Mutations in the pioneer transcription factor FOXA1 are a hallmark of estrogen receptor-positive (ER(+)) breast cancers. Examining FOXA1 in ~5,000 breast cancer patients identifies several hotspot mutations in the Wing2 region and a breast cancer-spe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a301bfbe753d5649c1f16465194a84e2
https://doi.org/10.1016/j.ccell.2020.08.003
https://doi.org/10.1016/j.ccell.2020.08.003
Autor:
Ryan G. Kruger, Hugh Y. Rienhoff, Evangelia Loizou, Scott A. Armstrong, Britta Will, Min Ye, Ross L. Levine, Alan Chramiec, Helai P. Mohammad, Andrei V. Krivtsov, Matthew Witkin, Daniel G. Tenen, Sheng F. Cai, Richard Koche, Monica Cusan, Ulrich Steidl, Kimberly N. Smitheman
Publikováno v:
Blood. 131(15)
Epigenetic regulators are recurrently mutated and aberrantly expressed in acute myeloid leukemia (AML). Targeted therapies designed to inhibit these chromatin-modifying enzymes, such as the histone demethylase lysine-specific demethylase 1 (LSD1) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::105949f675f6e4aed8cc77d5adbc0b54
https://pubmed.ncbi.nlm.nih.gov/29453291
https://pubmed.ncbi.nlm.nih.gov/29453291